Baloxavir marboxil - Roche/Shionogi

Drug Profile

Baloxavir marboxil - Roche/Shionogi

Alternative Names: RG 6152; S 033188; XOFLUZA

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer Roche; Shionogi
  • Class Antivirals; Dibenzothiepins; Esters; Pyridines; Small molecules; Triazines
  • Mechanism of Action Endonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza A virus infections; Influenza B virus infections
  • Registered Influenza virus infections
  • Preclinical Influenza A virus H5N1 subtype

Most Recent Events

  • 17 Jul 2018 Initial efficacy and adverse events data from the phase III CAPSTONE-2 trial in Influenza virus infections released by Shinonogi
  • 16 Jul 2018 Updated efficacy data from the phase III CAPSTONE-2 trial in Influenza virus infections released by Roche
  • 16 Jul 2018 Roche plans a phase III trial for Influenza virus infection in pediatric and severely ill hospitalised populations
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top